Tumor-Infiltrating Mast Cells in Angiosarcoma Correlate With Immuno-Oncology Pathways and Adverse Clinical Outcomes

被引:5
|
作者
Tai, Sarah Beishan [1 ,2 ]
Lee, Elizabeth Chun Yong [2 ]
Lim, Boon Yee [2 ]
Kannan, Bavani [2 ]
Lee, Jing Yi [2 ]
Guo, Zexi [2 ]
Ko, Tun Kiat [2 ]
Ng, Cedric Chuan -Young [2 ]
Teh, Bin Tean [3 ,4 ]
Chan, Jason Yongsheng [2 ,4 ,5 ]
机构
[1] Singapore Gen Hosp, Dept Nucl Med & Mol Imaging, Singapore, Singapore
[2] Natl Canc Ctr, Canc Discovery Hub, Singapore, Singapore
[3] Natl Canc Ctr, Lab Canc Epigenome, Singapore, Singapore
[4] Duke NUS Med Sch, Singapore, Singapore
[5] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
基金
英国医学研究理事会;
关键词
sarcoma; next-generation sequencing; immunotherapy; mast cells; immuno-oncology; ENDOTHELIAL GROWTH-FACTOR; CANCER; PROGNOSIS; LYMPHOMA; SURVIVAL;
D O I
10.1016/j.labinv.2024.100323
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Recent studies have described several molecular subtypes and deregulation of immuno-oncologic signaling pathways in angiosarcoma. Interestingly, mast cells were enriched in subsets of angiosarcoma, although their significance remains unknown. In this study, we aim to verify this observation using immunohistochemistry (H scores) and NanoString transcriptomic profiling and explore the association between mast cells with clinical and biological features. In the study cohort (N = 60), H scores showed a significant moderate correlation with NanoString mast cell scores (r = 0.525; P < .001). Both H score and NanoString mast cell scores showed a significant positive correlation (P < .05) with head and neck location, nonepithelioid morphology, and lower tumor grade. Mast cell enrichment significantly correlated with higher NanoString regulatory T-cell scores (H score, r = 0.32; P = .01; NanoString mast cell score, r = 0.27; P = .04). NanoString mast cell scores positively correlated with signaling pathways relating to antigen presentation (r = 0.264; P = .0414) and negatively correlated with apoptosis (r = -0.366; P = .0040), DNA damage repair (r = -0.348; P = .0064), and cell proliferation (r = -0.542; P < .001). Interestingly, in the metastatic setting, patients with mast cell-enriched angiosarcoma showed poorer progressionfree survival (median, 0.2 vs 0.4 years; hazard ratio = 3.05; P = .0489) along with a trend toward worse overall survival (median, 0.2 vs 0.6 years; hazard ratio, 2.86; P = .0574) compared with patients with mast cell-poor angiosarcoma. In conclusion, we demonstrated the presence of mast cells in human angiosarcoma and provided initial evidence of their potential clinical and biological significance. Future research will be required to elucidate their specific roles and mechanisms, which may uncover novel avenues for therapeutic intervention. (c) 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology
    Choi, Hae Woong
    Naskar, Manisha
    Seo, Ho Kyung
    Lee, Hye Won
    BIOMEDICINES, 2021, 9 (11)
  • [2] Resident Memory-Like Tumor-Infiltrating Lymphocytes (TILRM): Latest Players in the Immuno-Oncology Repertoire
    Smazynski, Julian
    Webb, John R.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [3] Tumor-Infiltrating Mast Cells in Colorectal Cancer as a Poor Prognostic Factor
    Wu, Xianrui
    Zou, Yifeng
    He, Xiaosheng
    Yuan, Ruixue
    Chen, Yufeng
    Lan, Nan
    Lian, Lei
    Wang, Fengwei
    Fan, Xinjuan
    Zeng, Yang
    Ke, Jia
    Wu, Xiaojian
    Lan, Ping
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2013, 21 (02) : 111 - 120
  • [4] Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy
    Pinard, Christopher J.
    Lagree, Andrew
    Lu, Fang-, I
    Klein, Jonathan
    Oblak, Michelle L.
    Salgado, Roberto
    Cardenas, Juan Carlos Pinto
    Brunetti, Barbara
    Muscatello, Luisa Vera
    Sarli, Giuseppe
    Foschini, Maria Pia
    Hardas, Alexandros
    Castillo, Simon P.
    AbdulJabbar, Khalid
    Yuan, Yinyin
    Moore, David A.
    Tran, William T.
    CANCERS, 2022, 14 (20)
  • [5] Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the International Immuno-Oncology Biomarkers Working Group
    Liu, Jiu-Yang
    Yang, Gui-Fang
    Chen, Fang-Fang
    Peng, Chun-Wei
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6815 - 6827
  • [6] Clinical Implications of Tumor-Infiltrating Immune Cells in Breast Cancer
    Zhang, Shi-Chao
    Hu, Zu-Quan
    Long, Jin-Hua
    Zhu, Gui-Ming
    Wang, Yun
    Jia, Yi
    Zhou, Jing
    Ouyang, Yan
    Zeng, Zhu
    JOURNAL OF CANCER, 2019, 10 (24): : 6175 - 6184
  • [7] Tumor-infiltrating tryptase+ mast cells predict unfavorable clinical outcome in solid tumors
    Hu, Guoming
    Wang, Shimin
    Cheng, Pu
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (04) : 813 - 821
  • [8] Molecular Pathways: Tumor-Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment
    Lu, Tangying
    Gabrilovich, Dmitry I.
    CLINICAL CANCER RESEARCH, 2012, 18 (18) : 4877 - 4882
  • [9] Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes
    Gibson, E. J.
    Begum, N.
    Koblbauer, I.
    Dranitsaris, G.
    Liew, D.
    McEwan, P.
    Monfared, A. A. Tahami
    Yuan, Y.
    Juarez-Garcia, A.
    Tyas, D.
    Lees, M.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 139 - 154
  • [10] Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes
    Grotz, Travis E.
    Vaince, Faaiza
    Hieken, Tina J.
    MELANOMA RESEARCH, 2013, 23 (02) : 132 - 137